FDA Approves Amgen’s Blincyto to Treat CD19-Positive Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia
The approval of Blincyto was based on results from the Phase III E1910 clinical trial, which found that the treatment...
